Suppr超能文献

在昆虫细胞中表达的重组肝素辅因子II的特性分析。

Characterization of recombinant heparin cofactor II expressed in insect cells.

作者信息

Ciaccia A V, Cunningham E L, Church F C

机构信息

Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill 27599-7035, USA.

出版信息

Protein Expr Purif. 1995 Dec;6(6):806-12. doi: 10.1006/prep.1995.0012.

Abstract

Recombinant human heparin cofactor II (rHCII) was expressed as a fully active protein in the High-Five insect cell line. A maximal protein concentration of 6 micrograms/10(6) cells was achieved 2 days postinfection. Approximately 40 micrograms of partially purified rHCII was routinely recovered from 50 ml of media after sequential heparin and Q-Sepharose affinity adsorption. rHCII had a slightly lower apparent molecular weight than blood plasma HCII (pHCII) due to differences in N-glycosylation. Like pHCII, rHCII formed a stable bimolecular complex with thrombin when assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The thrombin and chymotrypsin inhibitory properties of rHCII and pHCII were quite similar. In the absence of glycosaminoglycan, the thrombin inhibition rate (k2 x 10(-4) M-1 min-1) was 2.29 +/- 0.36 for rHCII and 3.38 +/- 0.34 for pHCII. Chymotrypsin inhibition rates (k2 x 10(-5) M-1 min-1) were 6.2 +/- 2.0 for rHCII and 8.0 +/- 2.6 for pHCII. In the presence of glycosaminoglycans, the maximal thrombin inhibition rate (k2 x 10(-3) M-1 min-1) for rHCII was 10.4 +/- 2.5 at 100 micrograms/ml heparin and 16.0 +/- 4.3 at 1000 micrograms/ml dermatan sulfate compared to 9.0 +/- 0.7 at 200 micrograms/ml heparin and 18.5 +/- 5.3 at 1000 micrograms/ml dermatan sulfate for pHCII. HCII inhibition of thrombin was blocked by a synthetic sulfated hirudin peptide in both the presence and the absence of glycosaminoglycan. The present report describes for the first time the expression and characterization of HCII in a baculovirus system and demonstrates the feasibility of using this system to obtain adequate amounts of biologically active rHCII for future structure-function studies.

摘要

重组人肝素辅因子II(rHCII)在High-Five昆虫细胞系中表达为一种完全有活性的蛋白质。感染后2天达到最高蛋白浓度6微克/10⁶个细胞。经肝素和Q-琼脂糖亲和吸附后,常规从50毫升培养基中回收约40微克部分纯化的rHCII。由于N-糖基化的差异,rHCII的表观分子量略低于血浆HCII(pHCII)。与pHCII一样,通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳评估时,rHCII与凝血酶形成稳定的双分子复合物。rHCII和pHCII的凝血酶和胰凝乳蛋白酶抑制特性非常相似。在没有糖胺聚糖的情况下,rHCII的凝血酶抑制率(k₂×10⁻⁴M⁻¹分钟⁻¹)为2.29±0.36,pHCII为3.38±0.34。胰凝乳蛋白酶抑制率(k₂×10⁻⁵M⁻¹分钟⁻¹)rHCII为6.2±2.0,pHCII为8.0±2.6。在有糖胺聚糖存在的情况下,rHCII在100微克/毫升肝素时的最大凝血酶抑制率(k₂×10⁻³M⁻¹分钟⁻¹)为10.4±2.5,在1000微克/毫升硫酸皮肤素时为16.0±4.3,而pHCII在200微克/毫升肝素时为9.0±0.7,在1000微克/毫升硫酸皮肤素时为18.5±5.3。在有和没有糖胺聚糖的情况下,合成硫酸化水蛭素肽均能阻断HCII对凝血酶的抑制作用。本报告首次描述了HCII在杆状病毒系统中的表达和特性,并证明了使用该系统获得足够量的具有生物活性的rHCII用于未来结构-功能研究的可行性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验